<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00919191</url>
  </required_header>
  <id_info>
    <org_study_id>CA-P-6805</org_study_id>
    <nct_id>NCT00919191</nct_id>
  </id_info>
  <brief_title>Evaluation of Irritation by Two Facial Gels Applied to Opposite Sides of the Face</brief_title>
  <official_title>An Investigator-Blind, Phase 4 Study Assessing the Facial Irritation Potential of Two Acne Treatment Products Using A Split-Face Model</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valeant Pharmaceuticals International, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Valeant Pharmaceuticals International, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to compare the skin irritation potential of two marketed gels for acne treatment,
      each applied to half of the face of healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At the Baseline Visit, following satisfaction of entry criteria and screening procedures, all
      subjects will be applying two products to their faces, each on one side only. The side of the
      face receiving each product is randomly assigned. One group will use Retin-A MICRO Gel,
      (tretinoin) 0.04% Pump on the left side of the face and Epiduo Gel (adapalene .1% and benzoyl
      peroxide 2.5%), on the right side of the face daily for 3 consecutive weeks after washing
      with study-supplied facial wash. The other group will use the same products, but on opposite
      sides of the face for three consecutive weeks after washing with the same study-supplied
      facial wash.

      Subjects will return to the study center every weekday morning for evaluation and application
      of both study products. Applications done on the weekends, will be done at home by the
      subject. At each visit the subject will be scored for cutaneous treatment effects by a
      blinded evaluator. At baseline and at the end of each week, subjects will be photographed and
      have chromometer readings.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparative Assessment of Facial Irritation and Cutaneous Effects.</measure>
    <time_frame>Daily, for 3 weeks</time_frame>
    <description>Expert Grader Assessment, including cumulative scores for Erythema and Dryness on a scale of 0=none to 8=severe</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Self Assessment of Burning/Stinging and Itching</measure>
    <time_frame>Daily, for 3 weeks</time_frame>
    <description>Cumulative scores of Subjects' self assessment of burning/stinging and itching on a score from 0=none to 3=severe</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Two interventions in split-face model</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily use in a split face model:
Tretinoin gel
Adapalene Benzoyl peroxide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tretinoin gel</intervention_name>
    <description>Tretinoin gel 0.04% used once daily in a split-face model</description>
    <arm_group_label>Two interventions in split-face model</arm_group_label>
    <other_name>Retin-A Micro Gel 0.04% Pump</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adapalene and Benzoyl peroxide</intervention_name>
    <description>Adapalene .1% and Benzoyl peroxide 2.5%</description>
    <arm_group_label>Two interventions in split-face model</arm_group_label>
    <other_name>Epiduo Gel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers

          -  Before screening, subjects (or legally authorized representative) must read and sign
             the IRB approved Informed Consent Form (includes HIPPA and Photo release)

          -  Subjects must have Fitzpatrick Skin Type I, II or III, and judged by the Investigator
             to have healthy skin

          -  Subject's bilateral facial skin must be clear of any confounding irritation, rashes,
             acne, rosacea, etc. prior to the study

          -  Subject must be free of systemic retinoids for at least 2 months

          -  Subject must not be using any topical retinoids, systemic antibiotics, nicotinamide or
             systemic steroids for 1 month prior to study start

          -  All other topical medications to face (e.g., steroids, antimicrobials, salicylic acid
             and benzoyl peroxide) and cosmetics containing retinols, AHA's and bleaching agents
             such as hydroquinone are to be discontinued at least 2 weeks prior to study initiation

          -  Subjects will not apply any emollients and cosmetics to the facial area 24 hours prior
             to study initiation

          -  Subject must not be planning to become pregnant or nursing before entering the study
             and during the study period. In addition if using birth control pills, subject must be
             stabilized for at least 2 months. If subject is of child bearing potential, subject
             must be using approved method of birth control. Approved methods are birth control
             pills, implants, patches or spermicide with condoms.

        Exclusion Criteria:

          -  Subjects who are pregnant or nursing

          -  Subjects who have a grade 1 or more for facial erythema

          -  Subjects who exhibit any skin condition (i.e., atopic dermatitis, seborrheic
             dermatitis, and psoriasis) or disease that may require concurrent therapy or may
             confound the evaluation of drug safety or efficacy

          -  Subjects who have a history of hypersensitivity to any of the formulation components
             listed in Appendix 1.

          -  Subjects who have received any experimental drug or used any experimental device 30
             days prior to initiation of study therapy

          -  Subjects who have excessive facial hair that may obstruct or hinder the evaluation of
             any reactions

          -  Subjects who use any known photosensitizing agents

          -  Subjects who presently have skin cancer or actinic keratosis on the face
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ana Rossi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Johnson &amp; Johnson Consumer and Personal Products Worldwide</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Skin Study Center</name>
      <address>
        <city>Broomall</city>
        <state>Pennsylvania</state>
        <zip>19008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm</url>
    <description>FDA's Drug Finder</description>
  </link>
  <results_reference>
    <citation>Leyden JJ, Nighland M, Rossi AB, Ramaswamy R. Irritation potential of tretinoin gel microsphere pump versus adapalene plus benzoyl peroxide gel. J Drugs Dermatol. 2010 Aug;9(8):998-1003.</citation>
    <PMID>20684151</PMID>
  </results_reference>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2009</study_first_submitted>
  <study_first_submitted_qc>June 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2009</study_first_posted>
  <results_first_submitted>December 28, 2009</results_first_submitted>
  <results_first_submitted_qc>February 24, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 10, 2010</results_first_posted>
  <last_update_submitted>February 14, 2012</last_update_submitted>
  <last_update_submitted_qc>February 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acne</keyword>
  <keyword>irritation</keyword>
  <keyword>objective sensory methods</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benzoyl Peroxide</mesh_term>
    <mesh_term>Tretinoin</mesh_term>
    <mesh_term>Adapalene</mesh_term>
    <mesh_term>Adapalene, Benzoyl Peroxide Drug Combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tretinoin and Adapalene Benzoyl Peroxide Facial Gels</title>
          <description>One group will use Retin-A MICRO Gel, (tretinoin) 0.04% Pump on the left side of the face and Epiduo Gel (adapalene .1% and benzoyl peroxide 2.5%), on the right side of the face daily for 3 consecutive weeks after washing with study-supplied facial wash. The other group will use the same products, but on opposite sides of the face for three consecutive weeks after washing with the same study-supplied facial wash.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tretinoin and Adapalene Benzoyl Peroxide Facial Gels</title>
          <description>One group will use Retin-A MICRO Gel, (tretinoin) 0.04% Pump on the left side of the face and Epiduo Gel (adapalene .1% and benzoyl peroxide 2.5%), on the right side of the face daily for 3 consecutive weeks after washing with study-supplied facial wash. The other group will use the same products, but on opposite sides of the face for three consecutive weeks after washing with the same study-supplied facial wash.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.1" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Comparative Assessment of Facial Irritation and Cutaneous Effects.</title>
        <description>Expert Grader Assessment, including cumulative scores for Erythema and Dryness on a scale of 0=none to 8=severe</description>
        <time_frame>Daily, for 3 weeks</time_frame>
        <population>All participants used both gels concurrently, on opposite sides of the face (split-face model)</population>
        <group_list>
          <group group_id="O1">
            <title>Tretinoin Facial Gel</title>
            <description>Tretinoin Facial Gel used once daily on one side of the face in a split face model</description>
          </group>
          <group group_id="O2">
            <title>Adapalene Benzoyl Peroxide Facial Gel</title>
            <description>Adapalene Benzoyl Peroxide Facial Gel used once daily on the alternate side of the face in a split-face model</description>
          </group>
        </group_list>
        <measure>
          <title>Comparative Assessment of Facial Irritation and Cutaneous Effects.</title>
          <description>Expert Grader Assessment, including cumulative scores for Erythema and Dryness on a scale of 0=none to 8=severe</description>
          <population>All participants used both gels concurrently, on opposite sides of the face (split-face model)</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cumulative Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="1.2"/>
                    <measurement group_id="O2" value="2.7" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cumulative Dryness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="5.3"/>
                    <measurement group_id="O2" value="6.2" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Self Assessment of Burning/Stinging and Itching</title>
        <description>Cumulative scores of Subjects' self assessment of burning/stinging and itching on a score from 0=none to 3=severe</description>
        <time_frame>Daily, for 3 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tretinoin Facial Gel</title>
            <description>Tretinoin Facial Gel used once daily on one side of the face in a split-face model</description>
          </group>
          <group group_id="O2">
            <title>Adapalene Benzoyl Peroxide Facial Gel</title>
            <description>Adapalene Benzoyl Peroxide Facial Gel used once daily on the alternate side of the face in a split-face model</description>
          </group>
        </group_list>
        <measure>
          <title>Self Assessment of Burning/Stinging and Itching</title>
          <description>Cumulative scores of Subjects' self assessment of burning/stinging and itching on a score from 0=none to 3=severe</description>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cumulative Burning/Stinging</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="2.1"/>
                    <measurement group_id="O2" value="3.7" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cumulative Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.7"/>
                    <measurement group_id="O2" value="1.9" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Tretinoin and Adapalene Benzoyl Peroxide Facial Gels</title>
          <description>One group will use Retin-A MICRO Gel, (tretinoin) 0.04% Pump on the left side of the face and Epiduo Gel (adapalene .1% and benzoyl peroxide 2.5%), on the right side of the face daily for 3 consecutive weeks after washing with study-supplied facial wash. The other group will use the same products, but on opposite sides of the face for three consecutive weeks after washing with the same study-supplied facial wash.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Lineberry, Associate Director, Clinical Operations</name_or_title>
      <organization>Valeant Pharmaceuticals International, Inc</organization>
      <phone>949-973-1153</phone>
      <email>David.Lineberry@valeant.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

